CGRP Inhibitors: A Promising New Class of Drugs for Migraine

Poseida Therapeutics’ Allogeneic CAR-T P-BCMA-ALLO1 Demonstrates 91% ORR in Enhanced Lymphodepletion Arm of R/R MM Study

Kiromic reported that the fourth patient to have been treated in the trial showed a 5.3% reduction in tumor size with regard to baseline.

Gene Therapy Will Be a Major Area of Interest for Attendees at MDA’s 2025 Conference

The ORR in the enhanced lymphodepletion arm was 100% in patients who had not previously received an antiBCMA therapy.

Paul Melmeyer, MPP, the executive vice president of public policy & advocacy at MDA

Paul Melmeyer, MPP;Noah Stansfield

Around the Helix: Cell and Gene Therapy Company Updates – October 9, 2024

Paul Melmeyer, MPP, the executive vice president of public policy & advocacy at MDA, discussed the growing interest in gene therapy for the annual meeting.

IRD Gene Therapy OCU400’s Phase 1/2 Trial

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

Arun Upadhyay, PhD, the chief scientific officer and head of research, development, and Medical at Ocugen

Arun Upadhyay, PhD;Noah Stansfield

In Light of Positive Initial Results, Ultragenyx Seeks to Add Higher Dose Cohort to Trial for Wilson Disease Gene Therapy UX701

Arun Upadhyay, PhD, the chief scientific officer and head of research, development, and Medical at Ocugen, also discussed future plans for the gene therapy, which is now in a phase 3 study.

Eric Crombez, MD, the chief medical officer at Ultragenyx

October 8th 2024

Kiromic BioPharma’s NSCLC T-cell Therapy Deltacel Continues to Provide Disease Stabilization in Updated Data

Ultragenyx noted that the fourth cohort would use a “moderately increased” dose and an optimized immunodulation regimen.

Related Content

Poseida Therapeutics’ Allogeneic CAR-T P-BCMA-ALLO1 Demonstrates 91% ORR in Enhanced Lymphodepletion Arm of R/R MM Study

Kiromic reported that the fourth patient to have been treated in the trial showed a 5.3% reduction in tumor size with regard to baseline.

Gene Therapy Will Be a Major Area of Interest for Attendees at MDA’s 2025 Conference

The ORR in the enhanced lymphodepletion arm was 100% in patients who had not previously received an antiBCMA therapy.

Paul Melmeyer, MPP;Noah Stansfield

Around the Helix: Cell and Gene Therapy Company Updates – October 9, 2024

Paul Melmeyer, MPP, the executive vice president of public policy & advocacy at MDA, discussed the growing interest in gene therapy for the annual meeting.

IRD Gene Therapy OCU400’s Phase 1/2 Trial

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

Arun Upadhyay, PhD;Noah Stansfield

In Light of Positive Initial Results, Ultragenyx Seeks to Add Higher Dose Cohort to Trial for Wilson Disease Gene Therapy UX701

Arun Upadhyay, PhD, the chief scientific officer and head of research, development, and Medical at Ocugen, also discussed future plans for the gene therapy, which is now in a phase 3 study.

October 8th 2024